Novo Nordisk announced a positive opinion from the EMA on July 25, 2024, for updating the Wegovy® label, which now reflects a 20% risk reduction in major cardiovascular events for adults with obesity and cardiovascular disease. This update highlights Wegovy®’s potential benefits beyond weight management, including a 15% reduction in cardiovascular deaths and 19% in deaths from any cause.